Literature DB >> 12744811

Rheumatic manifestations of hepatitis C infection.

Dimitrios Vassilopoulos1, Leonard H Calabrese.   

Abstract

Among chronic viral infections, hepatitis C virus (HCV) infection is uniquely associated with an array of rheumatic manifestations and autoimmune laboratory findings. These include, among others, arthralgias, arthritis, fatigue, fibromyalgia, vasculitis, and sialadenitis (Sjögren-like). The mechanisms that are involved in the pathogenesis of these diverse manifestations have not yet been clarified. Regardless of the direct or indirect pathogenetic role of HCV in these clinical entities, the concomitant presence of a chronic viral infection creates a number of diagnostic and therapeutic problems. This is particularly true when immunosuppressive therapy is needed for control of disease activity (eg, HCV-associated cryoglobulinemic vasculitis). The emerging treatment options for chronic HCV offer a major chance for viral eradication and conceivably for cure of these HCV-associated conditions. In this review, the recent advances in the epidemiology, pathogenesis, clinical findings, and treatment of HCV-associated rheumatic conditions are presented.

Entities:  

Mesh:

Year:  2003        PMID: 12744811     DOI: 10.1007/s11926-003-0067-8

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  33 in total

1.  Successful treatment of HCV-associated cryoglobulinaemic glomerulonephritis with a combination of interferon-alpha and ribavirin.

Authors:  R Misiani; P Bellavita; P Baio; R Caldara; S Ferruzzi; P Rossi; F Tengattini
Journal:  Nephrol Dial Transplant       Date:  1999-06       Impact factor: 5.992

2.  Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha.

Authors:  E Zuckerman; D Keren; G Slobodin; I Rosner; M Rozenbaum; E Toubi; E Sabo; I Tsykounov; J E Naschitz; D Yeshurun
Journal:  J Rheumatol       Date:  2000-09       Impact factor: 4.666

Review 3.  Hepatitis C virus infection mimicking primary Sjögren syndrome. A clinical and immunologic description of 35 cases.

Authors:  M Ramos-Casals; M García-Carrasco; R Cervera; J Rosas; O Trejo; G de la Red; J M Sánchez-Tapias; J Font; M Ingelmo
Journal:  Medicine (Baltimore)       Date:  2001-01       Impact factor: 1.889

4.  Interferon-alpha in combination with ribavirin as initial treatment for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis.

Authors:  G Garini; L Allegri; L Carnevali; W Catellani; P Manganelli; C Buzio
Journal:  Am J Kidney Dis       Date:  2001-12       Impact factor: 8.860

5.  Systemic vasculitis in patients with hepatitis C.

Authors:  P Cacoub; T Maisonobe; V Thibault; A Gatel; J Servan; L Musset; J C Piette
Journal:  J Rheumatol       Date:  2001-01       Impact factor: 4.666

Review 6.  Rheumatic disorders associated with hepatitis C.

Authors:  M R Lövy; G Starkebaum
Journal:  Baillieres Best Pract Res Clin Rheumatol       Date:  2000-09       Impact factor: 4.098

7.  In situ detection of hepatitis C virus RNA in salivary glands.

Authors:  J J Arrieta; E Rodríguez-Iñigo; N Ortiz-Movilla; J Bartolomé; M Pardo; F Manzarbeitia; H Oliva; D M Macías; V Carreño
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

Review 8.  Complex management issues: management of HCV in the atypical patient.

Authors:  S J Hadziyannis; D Vassilopoulos
Journal:  Baillieres Best Pract Res Clin Gastroenterol       Date:  2000-04

9.  Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C.

Authors:  P Cacoub; C Renou; E Rosenthal; P Cohen; I Loury; V Loustaud-Ratti; A M Yamamoto; A C Camproux; P Hausfater; L Musset; P Veyssier; G Raguin; J C Piette
Journal:  Medicine (Baltimore)       Date:  2000-01       Impact factor: 1.889

10.  Kinetics of hepatitis C (HCV) viraemia and quasispecies during treatment of HCV associated cryoglobulinaemia with pulse cyclophosphamide.

Authors:  J Thiel; T Peters; A Mas Marques; B Rösler; H H Peter; S M Weiner
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

View more
  6 in total

1.  Effects of combined antiviral therapy on asymptomatic mixed cryoglobulinemia in naive patients with chronic hepatitis C virus infection: a preliminary study.

Authors:  Emilio D'Amico; Caterina Chincoli; Pierluigi Cacciatore; Gabriella di Pasqua; Luana Cosentino; Giuseppe Riario-Sforza; Ernesta Pennese; Fabio Capani; Carlo Palazzi
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

Review 2.  Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management.

Authors:  Jennifer M Loftis; Annette M Matthews; Peter Hauser
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 3.  Viral hepatitis: review of arthritic complications and therapy for arthritis in the presence of active HBV/HCV.

Authors:  Dimitrios Vassilopoulos; Leonard H Calabrese
Journal:  Curr Rheumatol Rep       Date:  2013-04       Impact factor: 4.686

4.  Impact of hepatitis B and C co-infection on health-related quality of life in HIV positive individuals.

Authors:  Jennifer Gillis; Curtis Cooper; Sean Rourke; Sergio Rueda; Kelly O'Brien; Evan Collins; Anita Rachlis; Trevor A Hart; Janet Raboud
Journal:  Qual Life Res       Date:  2012-10-17       Impact factor: 4.147

5.  Pain-related anxiety mediates the relationship between depressive symptoms and pain interference in veterans with hepatitis C.

Authors:  Melissa H Adams; Travis I Lovejoy; Dennis C Turk; Steven K Dobscha; Peter Hauser; Benjamin J Morasco
Journal:  Gen Hosp Psychiatry       Date:  2015-07-17       Impact factor: 3.238

Review 6.  Virally associated arthritis 2008: clinical, epidemiologic, and pathophysiologic considerations.

Authors:  Dimitrios Vassilopoulos; Leonard H Calabrese
Journal:  Arthritis Res Ther       Date:  2008-09-18       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.